Introduction: Immunogenicity of antitumor necrosis factor-alpha (TNFα) agents has been proven to play a significant role in the variability of clinical responses among patients with chronic inflammatory diseases. However, its clinical impact on the outcome of patients with psoriasis and psoriatic arthritis receiving anti-TNFα treatment is not yet fully clear. Despite the high rates of efficacy of anti-TNFα agents in psoriasis, a substantial proportion of patients remain who experience a primary or secondary failure or significant side effects, which are potentially ascribable to immunogenicity. Areas covered: Topics include immunologic response elicited by anti-TNFα agents, the impact of immunogenicity on treatment response to anti-TNFα and the role played by immunogenicity in the lack of efficacy of anti-TNFα agents (infliximab, adalimumab and etanercept) in psoriasis. Expert opinion: Based on data available in the literature and the clinical experience of the authors, this article suggests the optimal approach to drug monitoring and antidrug antibody assay and the most effective use of biologic immunotherapies in this setting. Immunogenicity should be taken into account in the adoption of therapeutic choices in psoriatic patients, such as anti-TNFα agent intensification, or switching to another anti-TNFα agent or a drug with a different mechanism of action. © 2013 Informa UK, Ltd.

Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue? / Clara De, Simone; Paolo, Amerio; Giuseppe, Amoruso; Federico, Bardazzi; Anna, Campanati; Andrea, Conti; Paolo, Gisondi; Giulio, Gualdi; Claudio, Guarneri; Luca, Leoni; Francesco, Loconsole; Annamaria, Mazzotta; Maria Letizia, Musumeci; Stefano, Piaserico; Potenza, Concetta; Francesca, Prestinari. - In: EXPERT OPINION ON BIOLOGICAL THERAPY. - ISSN 1471-2598. - ELETTRONICO. - 13:12(2013), pp. 1673-1682. [10.1517/14712598.2013.848194]

Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?

POTENZA, Concetta;
2013

Abstract

Introduction: Immunogenicity of antitumor necrosis factor-alpha (TNFα) agents has been proven to play a significant role in the variability of clinical responses among patients with chronic inflammatory diseases. However, its clinical impact on the outcome of patients with psoriasis and psoriatic arthritis receiving anti-TNFα treatment is not yet fully clear. Despite the high rates of efficacy of anti-TNFα agents in psoriasis, a substantial proportion of patients remain who experience a primary or secondary failure or significant side effects, which are potentially ascribable to immunogenicity. Areas covered: Topics include immunologic response elicited by anti-TNFα agents, the impact of immunogenicity on treatment response to anti-TNFα and the role played by immunogenicity in the lack of efficacy of anti-TNFα agents (infliximab, adalimumab and etanercept) in psoriasis. Expert opinion: Based on data available in the literature and the clinical experience of the authors, this article suggests the optimal approach to drug monitoring and antidrug antibody assay and the most effective use of biologic immunotherapies in this setting. Immunogenicity should be taken into account in the adoption of therapeutic choices in psoriatic patients, such as anti-TNFα agent intensification, or switching to another anti-TNFα agent or a drug with a different mechanism of action. © 2013 Informa UK, Ltd.
2013
anti-tnfα agent; psoriasis; immunogenicity
01 Pubblicazione su rivista::01a Articolo in rivista
Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue? / Clara De, Simone; Paolo, Amerio; Giuseppe, Amoruso; Federico, Bardazzi; Anna, Campanati; Andrea, Conti; Paolo, Gisondi; Giulio, Gualdi; Claudio, Guarneri; Luca, Leoni; Francesco, Loconsole; Annamaria, Mazzotta; Maria Letizia, Musumeci; Stefano, Piaserico; Potenza, Concetta; Francesca, Prestinari. - In: EXPERT OPINION ON BIOLOGICAL THERAPY. - ISSN 1471-2598. - ELETTRONICO. - 13:12(2013), pp. 1673-1682. [10.1517/14712598.2013.848194]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/527982
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 63
  • ???jsp.display-item.citation.isi??? 59
social impact